Kumar PA, Patterson J, Karpagam P.Multiple antibiotic resistance profiles of Vibrio cholerae non-O1 and non-O139[J].Jpn J Infect Dis, 2009, 62(3):230-232.
[5]
Banerjee R, Das B, Balakrish NG, et al.Dynamics in genome evolution of Vibrio cholerae[J].Infect Genet Evol, 2014, 23:32-41.
[6]
Murhekar M, Dutta S, Ropa B, et al.Vibrio cholerae antimicrobial drug resistance, Papua New Guinea, 2009-2011[J].Western Pac Surveill Response J, 2013, 4(3):60-62.
[7]
Wang R, Lou J, Liu J, et al.Antibiotic resistance of Vibrio cholerae O1 El Tor strains from the seventh pandemic in China, 1961-2010[J].Int J Antimicrob Agents, 2012, 40(4):361-364.
[8]
Saha D, Karim MM, Khan WA, et al.Single-dose azithromycin for the treatment of cholera in adults[J].N Engl J Med, 2006, 354(23):2452-2462.
[9]
Leibovici-Weissman Y, Neuberger A, Bitterman R, et al.Antimicrobial drugs for treating cholera[J].Cochrane Database Syst Rev, 2014, 6:D8625.
[10]
卫生部疾病控制司.霍乱防治手册[M].5版.北京:人民卫生出版社, 1999:65.
[11]
Bauer AW, Kirby WM, Sherris JC, et al.Antibiotic susceptibility testing by a standardized single disk method[J].Am J Clin Pathol, 1966, 45(4):493-496.
[12]
Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing;twentieth informational supplement[S].America:Clinical and Laboratory Standards Institute, 2010.
[13]
Cariri FA, Costa AP, Melo CC, et al.Characterization of potentially virulent non-O1/non-O139 Vibrio cholerae strains isolated from human patients[J].Clin Microbiol Infect, 2010, 16(1):62-67.
[14]
Luo Y, Ye J, Jin D, et al.Molecular analysis of non-O1/non-O139 Vibrio cholerae isolated from hospitalised patients in China[J].BMC Microbiol, 2013, 13:52.
